CanaryTech's profile picture. A medical technology company using artificially powered intelligence and nano-technology to build revolutionary diagnostic equipment.

Canary Global Inc.

@CanaryTech

A medical technology company using artificially powered intelligence and nano-technology to build revolutionary diagnostic equipment.

Repost di Canary Global Inc.

BA.2.75.2 may be “a” concern, but it’s not “the” concern. What is worrying is the trend that happened in the last few months in Omicron, and more robust in the polytomy of BA.2.75 - The RBD region, which was highly conserved in the past, shows increasing plasticity. 1/4


Repost di Canary Global Inc.

Promises made… promises need to be kept, @JoeBiden. Thank you.

DrEricDing's tweet image. Promises made… promises need to be kept, @JoeBiden. Thank you.

Repost di Canary Global Inc.

Looking forward to hosting Dr Lisa Newman @BrighamSurgery and @DFCI_BreastOnc for Carolyn Kaelin visiting Professorship.

TariKingMD's tweet image. Looking forward to hosting Dr Lisa Newman @BrighamSurgery and @DFCI_BreastOnc for Carolyn Kaelin visiting Professorship.

Repost di Canary Global Inc.

Our chief fellow @Sunil_G_Iyer presenting important collaborative effort between @SylvesterCancer and @MSKCancerCenter to improve HCT utilization in racial minorities at the 15th. @AACR Conference on Cancer Care Disparities. #AACRdisp22 #bmtsm

amjimenezmd's tweet image. Our chief fellow @Sunil_G_Iyer presenting important collaborative effort between @SylvesterCancer and @MSKCancerCenter to improve HCT utilization in racial minorities at the 15th. @AACR Conference on Cancer Care Disparities. #AACRdisp22 #bmtsm

Repost di Canary Global Inc.

World… meet Mozzarella and her balsamic ears @darth

HighGloveSide25's tweet image. World… meet Mozzarella and her balsamic ears @darth
HighGloveSide25's tweet image. World… meet Mozzarella and her balsamic ears @darth

Repost di Canary Global Inc.

Published today: @TheLancet Commission on Covid-19: "a massive global failures" with recommendations going forward thelancet.com/commissions/co… It's a 57-page paper. I think this Figure and the 1-pager editorial summarize it well

EricTopol's tweet image. Published today: @TheLancet Commission on Covid-19:
"a massive global failures" with recommendations going forward 
thelancet.com/commissions/co…
It's a 57-page paper. I think this Figure and the 1-pager editorial summarize it well
EricTopol's tweet image. Published today: @TheLancet Commission on Covid-19:
"a massive global failures" with recommendations going forward 
thelancet.com/commissions/co…
It's a 57-page paper. I think this Figure and the 1-pager editorial summarize it well

Repost di Canary Global Inc.

Will you pray for home less pets ? 🙏 Like = Yes ✅️ Ignore = No ❌️

thehappydog_'s tweet image. Will you pray for home less pets ? 🙏

Like = Yes ✅️
Ignore = No ❌️

Repost di Canary Global Inc.

With #ESMO22 turning to history, on the plane back to 🇬🇷, Ι added a column of main outcomes/potential clinical relevance in my previous list of influential trials in #NSCLC 🙏@myESMO staff, officers,speakers,chairs, attendees for a magical experience! @OncoAlert #some #LCSM

g_mountzios's tweet image. With #ESMO22 turning to history, on the plane back to 🇬🇷, Ι added a column of main outcomes/potential  clinical relevance in my previous list of influential trials in #NSCLC

🙏@myESMO staff, officers,speakers,chairs, attendees for a magical experience! 
@OncoAlert  #some #LCSM

Repost di Canary Global Inc.

Has someone you know been diagnosed with lung cancer? Helping the patient in your life with resources they need can make a world of difference: bit.ly/3qhxPwC

LUNGFORCE's tweet image. Has someone you know been diagnosed with lung cancer? Helping the patient in your life with resources they need can make a world of difference: bit.ly/3qhxPwC

Repost di Canary Global Inc.

Day 4 #ESMO22 Highlights from #CommunityOncologists perspective: 1. #IFCT1701 - ICI in mNSCLC 2. #POSEIDON Update - mNSCLC @MLJohnsonMD2 3. #CodeBreak200 - KRAS G12C NSCLC @MLJohnsonMD2 #LCSM #MedTwitter #OncEd @HemOncFellows @OncoAlert @myESMO 1/9


Repost di Canary Global Inc.

Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC) ✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr) ✅ORR 28.1 vs 10.2 % ❎OS HR 1.01 ✅fewer gr. ≥3 & serious TRAEs  Endless discussion regarding the magnitude of benefit awaited @OncoAlert

JulienMazieres's tweet image. Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC)
✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr)
✅ORR 28.1 vs 10.2 %
❎OS HR 1.01
✅fewer gr. ≥3 & serious TRAEs 
Endless discussion regarding the magnitude of benefit awaited @OncoAlert
JulienMazieres's tweet image. Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC)
✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr)
✅ORR 28.1 vs 10.2 %
❎OS HR 1.01
✅fewer gr. ≥3 & serious TRAEs 
Endless discussion regarding the magnitude of benefit awaited @OncoAlert
JulienMazieres's tweet image. Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC)
✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr)
✅ORR 28.1 vs 10.2 %
❎OS HR 1.01
✅fewer gr. ≥3 & serious TRAEs 
Endless discussion regarding the magnitude of benefit awaited @OncoAlert
JulienMazieres's tweet image. Probably the most awaited trial #ESMO22. CODEBREAK200 (sotorasib vs doc in 2/3L NSCLC)
✅PFS HR 0.66 (5.6 vs 4.5 m / 24.8 vs 10.1% at 1 yr)
✅ORR 28.1 vs 10.2 %
❎OS HR 1.01
✅fewer gr. ≥3 & serious TRAEs 
Endless discussion regarding the magnitude of benefit awaited @OncoAlert

Repost di Canary Global Inc.

Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting! Standing room only. Is it tolerability that caused this? 57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert @IMDConline @bmsnews

DrDanielHeng's tweet image. Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting!  Standing room only. Is it tolerability that caused this?  57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert @IMDConline @bmsnews
DrDanielHeng's tweet image. Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting!  Standing room only. Is it tolerability that caused this?  57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert @IMDConline @bmsnews
DrDanielHeng's tweet image. Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting!  Standing room only. Is it tolerability that caused this?  57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert @IMDConline @bmsnews
DrDanielHeng's tweet image. Nivo IPI adjuvant RCC is negative. Larger than life @motzermd presenting!  Standing room only. Is it tolerability that caused this?  57% completed all cycles. Sizeable pT2 group and no M1NED may have made the population less high risk. @OncoAlert @IMDConline @bmsnews

Repost di Canary Global Inc.

A patient presents with a distended abdomen. His eyes look like this. What’s the diagnosis? #MedTwitter

AvrahamCooperMD's tweet image. A patient presents with a distended abdomen. His eyes look like this. What’s the diagnosis? 

#MedTwitter

Repost di Canary Global Inc.

Don't be numb to this wsj.com/articles/covid… by @jon_kamp

EricTopol's tweet image. Don't be numb to this
wsj.com/articles/covid… by @jon_kamp

Repost di Canary Global Inc.

Congratulations to⁩ ⁦⁦@CharlesSwanton⁩ for an elegant answer to the question of LC causality in never smokers! Opening the possibility of LC prevention with IL 1b inh. Similarly to tobacco exposure, we should reduce PM2.5 air pollution exposure. ⁦@myESMO

ElizabethDudnik's tweet image. Congratulations to⁩ ⁦⁦@CharlesSwanton⁩ for an elegant answer to the question of LC causality in never smokers! Opening the possibility of LC prevention with IL 1b inh. Similarly to tobacco exposure, we should reduce PM2.5 air pollution exposure. ⁦@myESMO⁩

Repost di Canary Global Inc.

#Lungcancer awareness month is November! Join us this #LCAM and show your support by either making or buying a white ribbon! Check out here for more white ribbon resources: bit.ly/3QpfvyD

lcfamerica's tweet image. #Lungcancer awareness month is November! Join us this #LCAM and show your support by either making or buying a white ribbon! Check out here for more white ribbon resources: bit.ly/3QpfvyD

Repost di Canary Global Inc.

Updated @NCCN guidelines recommends genetic testing in all women <50 yrs at breast ca dx.Our study in @JCO_ASCO ⬇️ has shown that this threshold will miss >10% of BRCA1/2 carriers.We need to expand testing to all women under 65 at breast ca dx to identify >95% of BRCA1/2 carriers

SidYadavMD's tweet image. Updated @NCCN guidelines recommends genetic testing in all women &amp;lt;50 yrs at breast ca dx.Our study in @JCO_ASCO ⬇️ has shown that this threshold will miss &amp;gt;10% of BRCA1/2 carriers.We need to expand testing to all women under 65 at breast ca dx to identify &amp;gt;95% of BRCA1/2 carriers

Repost di Canary Global Inc.

Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22 @OncoAlert

JulienMazieres's tweet image. Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22 @OncoAlert
JulienMazieres's tweet image. Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22 @OncoAlert
JulienMazieres's tweet image. Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22 @OncoAlert
JulienMazieres's tweet image. Dose matters !!! DESTINY-LUNG02 trial. Same efficacy, less toxicity including pneumonitis in HER2 mut #NSCLC with 5.4 vs 6.4 dose. Should be the standard dose. Please include patient in DESTINY-LUNG04 trial (exp arm dose is 5.4) #ESMO22 @OncoAlert

Repost di Canary Global Inc.

This is a coffee shop in Greece 🇬🇷 , which opens its door to stray dogs every night so they don freeze to death 😍😍

thehappydog_'s tweet image. This is a coffee shop in Greece 🇬🇷 , which opens its door to stray dogs every night so they don freeze to death 😍😍

Loading...

Something went wrong.


Something went wrong.